CJC-1295 + Ipamorelin 5mg — Vial Spec, Reconstitution Math & COA

Overview of the CJC-1295 + Ipamorelin 5mg Specification

A 5mg total mass research vial of CJC-1295 + Ipamorelin consists of a lyophilized, dual-component peptide matrix typically formulated at a 1:1 mass ratio (2.5mg CJC-1295 No DAC and 2.5mg Ipamorelin) or a custom molar equivalent. This specific vial specification is selected by research laboratories conducting short-duration bioassays, low-volume cell culture treatments, or initial proof-of-concept animal studies where minimizing reagent degradation across repeated thaw cycles is critical.

While PX1 Research specializes in high-yield, lot-verified CJC-1295 No DAC / Ipamorelin 10mg Blend configurations to serve extended high-throughput research, understanding the 5mg vial specification remains essential for researchers standardizing lower-volume micro-dosing assays. Whether evaluating lower total mass vials or larger batch sizes, bench scientists rely on standardized volumetric calculations across our complete catalog of research peptides to ensure experimental repeatability.

Receptor Binding Dynamics and Dual-Pathway Synergies

The combination of CJC-1295 and Ipamorelin targets two distinct receptor pathways within the anterior pituitary somatotrophs, orchestrating a complementary, dual-trigger release of growth hormone (GH). CJC-1295 operates as a synthetic analog of growth-hormone-releasing hormone (GHRH), binding directly to the GHRH receptor. Studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research, CJC-1295 stimulates intracellular cyclic adenosine monophosphate (cAMP) accumulation, accelerating GH synthesis and basal secretion.

Conversely, Ipamorelin acts as a selective agonist at the growth hormone secretagogue receptor (GHSR-1a), mimicking the endogenous hormone ghrelin. In vitro assays and rodent models demonstrate that activating GHSR-1a triggers a phospholipid-dependent intracellular calcium influx. When both pathways are activated concurrently, GHRH analog signal transduction and GHSR agonist signaling exert a synergistic effect, resulting in amplified, pulsatile GH release that significantly exceeds the additive outputs of either peptide tested in isolation.

Reconstitution Mathematics for 5mg Lyophilized Vials

Reconstituting a 5mg total peptide vial requires precise mathematical calculations to convert solid mass into standardized volumetric concentrations. Reagent preparation typically employs sterile Bacteriostatic Water (0.9% benzyl alcohol preserved) or sterile normal saline (0.9% NaCl), depending on downstream cellular compatibility requirements. Bench researchers must account for the combined mass (5000 micrograms total) when establishing final working concentrations.

To achieve target concentrations, specific diluent volumes must be added to the 5mg lyophilized cake:

• Reconstituting with 1.0 mL diluent yields a final total peptide concentration of 5.0 mg/mL (5000 µg/mL total; or 2.5 mg/mL per individual constituent in a 1:1 blend).

• Reconstituting with 2.0 mL diluent yields a final total peptide concentration of 2.5 mg/mL (2500 µg/mL total; or 1.25 mg/mL per constituent).

• Reconstituting with 2.5 mL diluent yields a final total peptide concentration of 2.0 mg/mL (2000 µg/mL total; or 1.0 mg/mL per constituent).

• Reconstituting with 5.0 mL diluent yields a final total peptide concentration of 1.0 mg/mL (1000 µg/mL total; or 0.5 mg/mL per constituent).

For complex dilution protocols or micro-liter level dispensing calculations, laboratory personnel should utilize our interactive reconstitution calculator to eliminate manual conversion errors.

Precision Aliquoting and Working Solution Handling

To maintain structural integrity during liquid handling, diluent must be introduced slowly against the interior glass wall of the vial. Direct high-velocity stream impact onto the lyophilized cake can induce physical shear stress, resulting in partial peptide denaturation or aggregate formation. The vial should be gently rolled between the palms or tilted slowly until complete dissolution is observed; vortexing or violent shaking must be strictly avoided.

Following complete reconstitution, working solutions should be aliquoted into low-binding polypropylene micro-centrifuge tubes. Standard lab grade glass or non-treated polystyrene can exhibit non-specific peptide adsorption, causing loss of active monomer concentration. Aliquoting limits ambient air exposure and prevents damage caused by multiple freeze-thaw cycles during longitudinal in vitro assays.

Thermal Stability and Storage Protocols

Lyophilized CJC-1295 + Ipamorelin 5mg vials demonstrate high thermal stability when stored in climate-controlled environments. Unreconstituted vials should be preserved at -20°C for short-to-medium term storage (up to 24 months) or -80°C for long-term biobanking. Keep lyophilized vials sealed in desiccated storage containers away from direct light exposure to prevent photo-oxidation.

Once reconstituted with bacteriostatic diluent, liquid solutions must be maintained at 2°C to 8°C under refrigeration. Preclinical stability testing indicates that reconstituted solutions remain chemically stable for up to 28 to 30 days under sterile 2–8°C conditions. If reconstituted with unpreserved sterile water, aliquots must be used immediately or frozen at -80°C to prevent microbial proliferation and rapid hydrolytic degradation.

Lot-Matched COA Verification, HPLC/MS, and Quality Standards

PX1 Research enforces strict analytical standards across all manufacturing lots. Every batch produced in our USA-based, ISO 9001 and GMP-compliant facilities undergoes independent testing by an accredited ISO 17025 laboratory prior to release. Every shipment is backed by third-party documentation available on our public lot-matched Certificate of Analysis database.

Analytical verification includes:

• High-Performance Liquid Chromatography (HPLC): Confirms chemical purity exceeds 98.0%, ensuring the absence of truncated peptide fragments or synthesis byproducts.

• Liquid Chromatography-Mass Spectrometry (LC-MS): Verifies exact mass spectrographic identity for both CJC-1295 and Ipamorelin molecular weights.

• Endotoxin Quantitation: Limulus Amebocyte Lysate (LAL) testing guarantees endotoxin levels remain strictly below <0.05 EU/mg, preventing lipopolysaccharide-induced inflammatory artifacts in sensitive cell lines.

• Bioburden Analysis: Sterile culture testing confirms zero bacterial or fungal contamination per lot.

Comparative Analysis: CJC-1295/Ipamorelin vs. Sermorelin and GHRP-2

When evaluating somatotroph Axis secretagogues, bench investigators frequently compare the CJC-1295/Ipamorelin combination to individual secretagogues like Sermorelin 5mg or alternative hexapeptides such as GHRP-2 research specifications. While Sermorelin represents a truncated 29-amino-acid GHRH fragment with a short biological half-life (approx. 8–12 minutes in animal models), CJC-1295 (Modified GRF 1-29) features four amino acid substitutions that increase resistance to dipeptidyl peptidase-IV (DPP-IV) enzymatic cleavage, extending half-life significantly. Furthermore, pairing CJC-1295 with Ipamorelin—rather than older ghrelin mimetics like GHRP-2 or GHRP-6—significantly improves receptor selectivity, eliminating unwanted surges in adrenocorticotropic hormone (ACTH), cortisol, and prolactin observed in preclinical rodent models. Detailed mechanical comparisons are further elaborated in our CJC-1295 No DAC research monograph and Ipamorelin peptide overview.

Format Selection: 5mg vs. 10mg Vial Configuration Considerations

Choosing between a 5mg vial specification and a 10mg vial configuration depends entirely on protocol design, reagent consumption rate, and study duration. The 5mg format is ideal for low-volume bench work, exploratory cell line exposures, or brief pilot studies where liquid volume must be consumed rapidly within a 14-day window to prevent solution aging.

Conversely, 10mg dual-blend configurations (such as PX1's 10mg CJC-1295 No DAC / Ipamorelin blend) offer superior volumetric efficiency and reduced cost-per-milligram for high-throughput screening or multi-subject animal cohort research. Institutional laboratories running ongoing trial series can register for wholesale accounts for institutional laboratories to obtain bulk lot reserves, or consult the PX1 research library for protocol optimization resources.

Preclinical Research Focus: Somatotrophic Axis and Tissue Repair

In vitro data and animal research models consistently highlight the role of dual GHRH/GHSR activation in modulating downstream endocrine and paracrine cascades. Co-administration stimulates pulsatile growth hormone release from somatotrophs, which subsequently binds to hepatic GH receptors to upregulate gene transcription and systemic secretion of Insulin-like Growth Factor 1 (IGF-1).

Preclinical studies suggest that sustained, physiological elevations in systemic and localized IGF-1 promote satellite cell proliferation, accelerate collagen type I and III synthesis, and increase myoblast differentiation in damaged skeletal muscle and connective tissue models. Investigators studying extracellular matrix dynamics, tendon-to-bone integration, and dermal wound repair utilize these dual-agonist mechanisms to quantify rate-of-healing metrics in controlled experimental environments.